Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Secures Strategic Investments
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Announces $15 Million Offering with Existing Investors
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.